Prophylactic thyroidectomy in multiple endocrine neoplasia: The impact of molecular mechanisms of RET proto-oncogene

Langenbeck's Archives of Surgery

Volumn 388, Issue 1, 2003, Pages 17-26

  Frilling, Andrea ^a   Weber, Frank ^a   Tecklenborg, Carsten ^a   Broelsch, Christoph Erich ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Multiple endocrine neoplasia 2; Prophylactic thyroidectomy; RET proto oncogene mutations

Indexed keywords

ARGININE; CYSTEINE; PROTEIN RET; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

CHROMOSOME 10Q; GANGLIONEUROMA; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOTE; HUMAN; HYPERPARATHYROIDISM; MISSENSE MUTATION; MULTIPLE ENDOCRINE NEOPLASIA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; GENETICS; GENOTYPE; LYMPH NODE METASTASIS; PHENOTYPE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYROID TUMOR;

GENOTYPE; HUMANS; LYMPHATIC METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; PHENOTYPE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0043029208     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-003-0368-4     Document Type: Review

References (70)

1. Frilling A, Röher H-D, Ponder BAJ (1994) Presymptomatic screening for medullary thyroid carcinoma in patients with multiple endocrine neoplasia type 2A. World J Surg 18:557-582
2. Simpson NE, Kidd KK, Goodfellow PJ, McDermid H, Myers S, Kid JR, Jackson CE, Duncan AM, Farrer LA, Brasch K (1987) Assignment of multiple endocrine neoplasia type 2a to chromosome 10 by linkage. Nature 328:528-530
3. Matthew CGP, Chin KS, Easton DF, Thorpe K, Carter C, Ilou GI, Fong S-L, Bridges CDB, Haak H, Nieuwenhuijzen Kruseman AC, Schifter S, Hansen HH, Telenius H, Telenius-Berg M, Ponder BAJ (1987) A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328:527-528
4. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC Hum Mol Genet 2:851-856
5. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ (1993) Germ-line mutation of RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460
6. Schuchardt A, Dàgati V, Larsson-Blomberg L, Costantini F, Pachnis V (1994) Defects in the kidney and enteric nervous sytem of mice lacking the tyrosine kinase receptor Ret. Nature 367:380-383
7. Hansford JR, Mulligan LM (2000) Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 37:817-827
8. Treanor JJS, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj-Bello A, Davies AM, Asai N, Takahas M, Vandlen R, Henderson CE, Rosenthal A (1996) Characterization of a multicomponent receptor for GDNF. Nature 382:80-83
9. Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sieber BA, Grigoriou M, Kilkenny C, Salazar-Gruezo E, Pachnis V, Arumae U (1996) Functional receptor for GDNF encoded by the c-RET proto-oncogene. Nature 381:785
10. Takahashi M (2001) The GDNF/RET signaling pathway and human disease. Cytokine Growth Factor Rev 12:361-373
11. Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Cupples R. Louis JC, Hu S, Altrock BW, Fox GM (1996) GDNF-induce activation of the RET protein tyrosine kinase is mediated by GDNFR-a, a novel receptor for GDNF. Cell 85:1113-1124
12. Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS, Leitner ML, Araki T, Johnson EM Jr, Milbrandt J (1998) Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRa2-RET receptor complex. Neuron 21:1291-1302
13. Klein RD, Sherman D, Ho WH, Stone D, Bennett GL, Moffat B, Vandlen R, Simmons L, Gu Q, Hongo JA, Devaux B, Poulsen K, Armanini M, Nozaki C, Asai N, Goddard A, Phillips H, Henderson CE, Takahashi M, Rosenthal A (1998) A gpi-linked protein that interacts with RET to form a candidate neurturin receptor. Nature 392:210
14. Trupp M, Scott R, Whittemore SR, Ibanez CF (1999) Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signalling in neuronal cells. J Biol Chem 274:20885-20894
15. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H (1988) Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3:571-578
16. Anders J, Kjar S, Ibanez CF (2001) Molecular modelling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domain and calcium-binding site. J Biol Chem 276:35808-35817
17. Myers SM, Eng C, Ponder BAJ, Mulligan LM (1995) Characterization of RET proto-oncogene 3′splicing variants and polyadenylation sites: a novel C terminus for RET. Oncogene 11:2039-2045
18. Segouffin-Cariou C, Billaud M (2000) Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 275:3568-3576
19. Hansford JR, Mulligan LM (2000) Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 37:817-827
20. Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono Y, Kumi K, Kurokawa K, Yoshiki M, Imai T, Funahashi H, Nakao A, Takahashi M (2000) Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19:4469-4475
21. Borrello MG, Mercalli E, Perego C, Degl Innocenti D, Ghizzoni S, Arighi E, Eroini B, Rizzetti BG, Pierotti MA (2002) Differential interaction of Enigma protein with the two RET isoforms. Biochem Biophys Res Commun 296:515-522
22. Kurokawa K, Iwashita T, Murakami H, Hayashi H, Kawai K, Takahashi M (2001) Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction. Oncogene 20:1929-1938
23. Murakami H, Iwashita T, Asai N, Shimono Y, Iwata Y, Kawai K, Takahashi M (1999) Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signaling molecules mediated by Ret with the MEN 2B mutation. Biochem Biophys Res Commun 262:68-75
24. Chiariello M, Visconti R, Carlomagno F, Melillo MM, Bucci C, de Franciscis V, Fox GM, Jing S, Coso OA, Gutkind JS, Fusco A, Santoro M (1998) Signaling of the RET receptor tyrosine kinase through the c-Jun NH2-terminal protein kinase (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene 16:2435-2445
25. Donis-Keller H (1995) The RET proto-oncogene and cancer. J Int Med 238:319-325
26. Mulligan LM, Marsh JD, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ, Gagel RF, Takai S-I, Noll WW, Fink M, Raue F, Lacroix A, Thibodeau SN, Frilling A, Ponder BAJ, Eng C (1995) Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238: 343-346
27. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, Ploos van Amste HK, Lips CJM, Nishisho I, Takai S-I, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BAJ, Mulligan LM (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579
28. Mulligan LM, Eng C, Attie T, Lyonnet S, Marsh DJ, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A, Venter DJ, Munnich A Ponder BAJ (1994) Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 3:2163-2167
29. Frank-Raue K, Höppner W, Frilling A, Kotzerke J, Dralle H, Haas R, Mann K, Seif F, Kirchner R, Rendl J, Deckart HF, Ritter MM, Hampel R, Klempa J, Scholz GH, Group GMTCS (1996) Mutations of the RET proto-oncogene in German MEN families: relation between genotype and phenotype. J Clin Endocrinol Metab 81:1780-1783
30. Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, Calmettes C, Modigliani E, Lenoir GM (1994) RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 3:1939-1943
31. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BA (1995) A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10:509-513
32. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth, Grussendorf M, Raue F, Ritter MM, Höppner W (1998) A new hot spot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770-774
33. Bolino A, Schuffenecker I, Yin L, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, Tourniaire J, Lenoir GM, Romeo G (1995) RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10:2415-2419
34. Fattoruso O, Quadro L, Libroia A, Verga U, Lupoli G, Cascone E, Colantuoni V (1998) A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma. Hum Mutat 1: 167-171
35. Feldmann GL, Edmonds MW, Ainsworth PJ, Schuffenecker I, Lenoir GM, Saxe AW, Talpos GB, Roberson J, Petrucelli N, Jackson CE (2000) Variable expression of familial medullary thyroid carcinoma (FMTC) due to a RET V804 M (CTG→ATG) mutation. Surgery 128:93-98
36. Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L, Maes B, Frederique S, Giraud S, Bezieau S, Kottler ML, Morange S, Conte-Devolx B, The French Tumor Study Group (GETC) (2001) Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab 86:3746-3753
37. Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PLM, Mulligan LM, Zajac JD, Robinson BG, Eng C (1997) Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 82:3902-3904
38. Niccoli-Sire P, Murat A, Baudin E, Henry JF, Proye C, Bigorgne JC, Bstandig B, Modigliani E, Morange S, Schlumberger M, Conte-Devoix B, The French Tumor Study Group (GETC) (1999) Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: results in 71 thyroidectomized patients. Eur J Endocrinol 141:468-474
39. Fitze G, Scherz M, Bredow J, Saeger HD, Roesner D, Schackert HK (2002) Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Ann Surg 236:570-575
40. Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, Iwata Y, Kawai K, Asai M, Kurokawa K, Kajta H, Takahiashi M (1999) Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2b and familial medullary thyroid carcinoma. Oncogene 18:3919-3922
41. Bocciardi R, Mograbi B, Pasini B, Borello MG, Pierotti MA, Bourget I, Fischer S, Romeo Giovanni, Rossi B (1997) The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene 15:2257-2265
42. Smith DP, Houghton C, Ponder BAJ (1997) Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15:1213-1217
43. Bartsch DK, Hasse C, Schug C, Barth P, Rothmund M, Höppner W (2000) A RET double mutation in the germline of a kindred with FMTC. Exp Clin Endocrinol Diabetes 108:128-132
44. Koch CA, Huang S, Vortmeyer AO, Zhuang Z, Chrousos GP, Pacak K (2000) A patient with MEN 2 and multiple mutations of RET in the germline. Exp Clin Endocrinol Diabetes 108:493
45. Höppner W, Ritter MM (1997) A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet 6:587-590
46. Höppner W, Dralle H, Brabant G (1998) A duplication of 9 base pairs in the critical cysteine rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A. Hum Mutat 1:128-130
47. Tessitore A, Sinisi AA, Pasquali D, Cardone M, Vitale D, Bellastella A, Collantuoni V (1999) A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET proto-oncogene. J Clin Endocrinol Metab 84:3522-3527
48. Committee on Genetics (2000) Molecular genetic testing in pediatric practice: a subject review. Pediatrics 106:1494-1497
49. Delbridge L, Robinson B (1998) Genetic and biochemical screening for endocrine disease. III. Costs and logistics. World J Surg 22:1212-1217
50. Skinner MA, De Benedetti MK, Moley JF, Norton JA, Wells SA (1996) Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg 1:177-181, discussion 181-182
51. Wells SA Jr, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton B, Ivanovich JL, DeBenedetti MK, Dilley WG, Moley JF, Norton JA, Donis-Keller H (1994) Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220:237-250
52. Wells SA Jr, Skinner MA (1998) Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 106:29-34
53. Dralle H, Gimm O, Simon D, Frank-Raue K, Görtz G, Niederle B, Wahl RA, Koch B, Walgenbach S, Hampel R, Ritter MM, Spelsberg F, Heiss A, Hinze R, Höppner W (1998) Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22:744-751
54. Rodriquez Gonzales JM, Balsalobre MD, Pomares F, Torregrosa NM, Rios A, Carbonell P, Glower G, Sola J, Tebar J, Parrilla P (2002) Prophylactic thyroidectomy in MEN 2A syndrome: experience in a single center. J Am Coll Surg 195:159-166
55. Learoyd DL, Marsh DJ, Richardson AL, Twigg SM, Delbridge L, Robinson BG (1997) Genetic testing for familial cancer. Arch Surg 132:1022-1025
56. Lallier M, St-Vil D, Giroux M, Huot C, Gabourcy L, Oligny L, Desjardins JG (1998) Prophylactic thyroidectomy for medullary thyroid carcinoma in gene carriers of MEN 2 syndrome. J Pediatr Surg 33:846-848
57. Klein I, Esik O, Homolya V, Szeri F, Varadi A (2001) Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial thyroid carcinoma syndromes in Hungary. J Endocrinol 170:661-666
58. Pacini F, Romei C, Miccoli P, Elisei R, Molinaro E, Mancusi F (1995) Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery 118:1031-1035
59. van Heurn LWE, Schaap C, Sie G, Haagen AAM, Gerver WJ, Freling G, van Amstel PHK, Heinemann E (1999) Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg 34:568-571
60. Sanso GE, Domene HM, Garcia Rudaz MC, Pusiol E, de Mondino AK, Ronue M, Ring A, Perinetti H, Elsner B, Iorcansky S, Barotini M (2002) Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children. Cancer 94:323-330
61. La-Quaglia MP, Telander RL (1997) Differentiated and medullary thyroid cancer in childhood and adolescences. Semin Pediatr Surg 6:42-49
62. Iihara M, Yamashita T, Okamoto T, Kanabe M, Yamazaki K, Egawa S (1997) A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary carcinoma in Japan. Jpn J Clin Oncol 27:128-134
63. O'Rioardan DS, O'Brien T, Crotty TB, Gharib H, Grant CS, van Heerden JA (1995) Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery 118:936-942
64. Torre M, Martucciello G, Ceccherini I, Lerone M, Aicardi M, Gambini C, Jasonni V (2002) Diagnostic and therapeutic approach to multiple endocrine neoplasia type 2B ind pediatric patients. Pediatr Surg Int 18:378-383
65. Gimm O, Niederle BE, Weber T, Bockhorn M, Ukkat J, Brauckhof M, Thanh PN, Frilling A, Klar E, Niederle B, Dralle H (2002) RET proto-oncogene mutations affecting codon 790/791: a mild form of multiple endocrine neoplasia 2A? Surgery 132:952-959
66. Frohnauer MK, Decker RA (2000) Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery 128:1052-1058
67. Lecube A, Hernandez C, Oriola J, Galard R, Gemar E, Mesa J, Simo R (2002) V804 M RET mutation and familial medullary thyroid carcinoma: report of a large family with expression of the disease only in the homozygous gene carriers. Surgery 131:509-514
68. Lombardo F, Baudin E, Chiefari E, Arturi F, Bardett S, Caillou B, Conte C, Dallapiccola B, Guiffrida D, Bidart JM, Schlumberger M, Filetti S (2002) Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab 87:1674-1680
69. Hansen HS, Terring H, Godballe C, Jäger AC, Nielsen FC (2000) Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome? Cancer 89:863-867
70. Dackiw AP, Kuerer HM, Clark OH (2002) Current national health insurance policies for thyroid cancer prophylactic surgery in the United States. World J Surg 26:903-906